Warfarin Dosing Put To The Test: Early Results From Medco/Mayo Research
This article was originally published in The Gray Sheet
Executive Summary
Nearly three-fourths of early patient participants in a warfarin research project appear to need non-standard dosing of the drug based on genetic screening, Medco reported during its recent analyst day Nov. 16
You may also be interested in...
Clinicians Split On Warfarin Gene Testing As A New Standard Of Care
FDA's drug and device centers are increasingly putting their weight behind the use of genetic tests to determine proper dosing of the anti-clotting drug warfarin, but convincing doctors is proving a bigger challenge
Clinicians Split On Warfarin Gene Testing As A New Standard Of Care
FDA's drug and device centers are increasingly putting their weight behind the use of genetic tests to determine proper dosing of the anti-clotting drug warfarin, but convincing doctors is proving a bigger challenge
Medco Gets Personal: LabCorp Agreement Pairs Cancer Med With AmpliChip
The pharmacy benefit manager Medco is working with the Laboratory Corporation of America to develop data on a personalized medicine approach to the use of the breast cancer drug tamoxifen